---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107014"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:10:20.703558+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback

## Summary
- Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).
- Net income $89.9M ($1.30 basic EPS) vs $1.2M ($0.02) in Q3 2024; driven by $62.3M fair-value gains on equity investments.
- Income from operations $34.6M, down 20% primarily due to non-recurring R&D expense.
- Board authorized $125M share repurchase program; $192.5M of convertible notes converted into 11.1M shares in August.
- ZEVTERA U.S. launch in July; zoliflodacin PDUFA Dec 15, 2025; investments: Armata $15M, Lyndra $10.2M, Beacon Biosignals $17.5M.

## SEC filing metadata
- accession: 0001104659-25-107014
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465925107014/0001104659-25-107014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465925107014/tm2530226d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107014
- JSON: https://secwatch.observer/filing/0001104659-25-107014.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.